Professor Jean-Michel Dogné was born on June 8, 1973, in Liège, Belgium. He obtained his Pharm. D. from the University of Liège (BE) in 1996 and continued his studies in the laboratory of medicinal chemistry at the same university, where he received his Ph.D. in pharmaceutical sciences in November 2000. He was appointed Professor at the University of Namur (BE) in 2005 where he is currently head of the Department of Pharmacy. His teaching activities cover drug development, medicinal chemistry, human biochemistry, drug safety and pharmacovigilance. He is the co-founder of the Namur thrombosis and hemostasis center (NTHC), the Namur nanosafety center (NNC), and the Namur Drug Design & Discovery Centre (NAMEDIC). His research interests include the development and monitoring of the antiplatelet and anticoagulant agents, the hemocompatibility of biomaterials, and nanotoxicology. He is the author or co-author of more than 200 papers and abstracts published in peer-review journals, including blood, circulation, trends in pharmacological sciences, journal of medicinal chemistry, thrombosis and hemostasis, and journal of thrombosis and hemostasis (Scopus August 2013: H-index: 25, citations: 2179). He also developed a strong and recognized expertise in pharmaceutical regulatory affairs and more particularly drug safety and pharmacovigilance. He is an expert in pharmacovigilance at the Federal Agency for Medicines and Health Products (BE) since January 2006 (Signal management; PSUR, PASS, and RMP assessments). He is the past Belgian delegate at the Pharmacovigilance Working Party (PhVWP) of the EMA (2006-2012). He was appointed Belgian effective member of the Pharmacovigilance Risk Assessment Committee (PRAC) of the EMA in July 2012. His specific areas of expertise in the field of pharmacovigilance cover the safety of medicines for selected systems/organ classes (Hematological and cardiovascular ADRs, medicines affecting the QT interval), vaccine safety, risk management plans, risk minimisation measures, signal detection and signal management, quality in pharmacovigilance, pharmacogenomics and pharmacogenetics of medicines. He actively participated in the EMA working groups of the task force for implementing the new legislation in pharmacovigilance at national and international levels as well as in the development and reviewing of GVP guidelines. He is one of the authors of the concept paper on the conduct of pharmacovigilance for medicines with pharmacogenomics associations under developement at the EMA level.